ACHV | Achieve Life Sciences, Inc.

Healthcare | Biotechnology | Canada | NASD

Index	-	P/E	-	EPS (ttm)	-3.76	Insider Own	0.30%	Shs Outstand	20.93M	Perf Week	19.29%
Market Cap	141.07M	Forward P/E	-	EPS next Y	-1.69	Insider Trans	8.65%	Shs Float	19.29M	Perf Month	-21.90%
Income	-43.80M	PEG	-	EPS next Q	-0.42	Inst Own	15.40%	Short Float / Ratio	3.28% / 3.51	Perf Quarter	31.64%
Sales	-	P/S	-	EPS this Y	2.10%	Inst Trans	2.38%	Short Interest	0.63M	Perf Half Y	140.71%
Book/sh	0.02	P/B	337.00	EPS next Y	0.00%	ROA	-161.40%	Target Price	28.57	Perf Year	-0.30%
Cash/sh	0.79	P/C	8.55	EPS next 5Y	15.00%	ROE	-762.70%	52W Range	2.00 - 10.30	Perf YTD	175.10%
Dividend	-	P/FCF	-	EPS past 5Y	61.00%	ROI	-	52W High	-34.56%	Beta	1.55
Dividend %	-	Quick Ratio	0.90	Sales past 5Y	-	Gross Margin	-	52W Low	237.00%	ATR	0.66
Employees	16	Current Ratio	0.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.14	Volatility	7.27% 9.78%
Optionable	Yes	Debt/Eq	41.00	EPS Q/Q	37.30%	Profit Margin	-	Rel Volume	0.80	Prev Close	6.46
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 09 AMC	Payout	-	Avg Volume	180.29K	Price	6.74
Recom	1.70	SMA20	-10.57%	SMA50	-6.73%	SMA200	46.75%	Volume	144,559	Change	4.33%

Date	Action	Analyst	Rating Change	Price Target Change
May-10-23	Reiterated	Maxim Group	Buy	$8 → $20
Jun-23-21	Initiated	Oppenheimer	Outperform	$23

May-25-23 09:00AM	Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering (GlobeNewswire) -6.07%
07:16AM	ACHV: ORCA-3 Topline (Zacks Small Cap Research)
May-24-23 06:10AM	Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) Shift From Loss To Profit (Simply Wall St.)
May-23-23 02:46PM	Can't Kick the Bud? Achieve's Cytisinicline Proves Promising in Phase 3 Smoking Cessation Trial (Benzinga) -23.80%
06:00AM	Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial (GlobeNewswire)
08:00AM	Loading…
May-17-23 08:00AM	Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank (GlobeNewswire)
May-10-23 09:08AM	ACHV: First Quarter Results (Zacks Small Cap Research) +12.71%
05:57AM	Q1 2023 Achieve Life Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-23 04:05PM	Achieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Apr-26-23 08:00AM	Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023 (GlobeNewswire)
Apr-24-23 05:27AM	ACHV: ORCA-V1 Readout (Zacks Small Cap Research)
Apr-20-23 02:22PM	Want To Quit Smoking? Achieve Life Sciences Reports Successful E-Cigarette Cessation Benefit With Cytisinicline Treatment (Benzinga)
08:00AM	Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline (GlobeNewswire)
Apr-14-23 08:00AM	Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference (GlobeNewswire)
Mar-30-23 08:00AM	Achieve Life Sciences Announces Refresh to Board of Directors (GlobeNewswire) +5.86%
08:00AM	Loading…
Mar-29-23 08:00AM	Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation (GlobeNewswire) +7.57%
Mar-20-23 10:46PM	Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2022 Earnings Call Transcript (Insider Monkey)
05:27AM	ACHV: 2022 Financial and Operational Results (Zacks Small Cap Research)
Mar-17-23 08:00AM	Achieve Life Sciences Announces Granting of New Hire Inducement Award (GlobeNewswire)
05:48AM	Q4 2022 Achieve Life Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-16-23 04:05PM	Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update (GlobeNewswire)
Mar-08-23 08:00AM	Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation (GlobeNewswire)
Mar-03-23 08:00AM	Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting (GlobeNewswire) +7.79%
Mar-02-23 08:00AM	Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023 (GlobeNewswire)
Feb-15-23 05:42AM	Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) top owners are individual investors with 56% stake, while 43% is held by institutions (Simply Wall St.) -15.52%
Feb-07-23 08:00AM	Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation (GlobeNewswire)
Feb-02-23 08:00AM	Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-27-23 04:30PM	Achieve Life Sciences Announces Granting of New Hire Inducement Award (GlobeNewswire)
Jan-09-23 08:00AM	Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation (GlobeNewswire) +7.28%
Dec-29-22 06:02AM	Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2022 Earnings Call Transcript (Insider Monkey)
08:00AM	Loading…
Dec-21-22 08:00AM	Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation (GlobeNewswire)
Nov-21-22 06:01AM	ACHV: 3Q:22 Results: Target Enrollments Reached (Zacks Small Cap Research)
Nov-15-22 08:00AM	Achieve Life Sciences Announces Private Placement of $18.9 Million (GlobeNewswire) +5.45%
Nov-14-22 04:05PM	Achieve Reports Financial Results for Third Quarter 2022 and Provides Corporate Update (GlobeNewswire)
Nov-08-22 08:00AM	Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial (GlobeNewswire)
Oct-31-22 08:00AM	Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022 (GlobeNewswire)
Sep-27-22 08:00AM	Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation (GlobeNewswire) -7.42%
Sep-07-22 08:00AM	Achieve Life Sciences Announces Participation at Fall Investor Conferences (GlobeNewswire)
Aug-15-22 06:16AM	ACHV: Autumn Enrollment Completion for ORCA-3 (Zacks Small Cap Research) +12.80%
Aug-11-22 04:05PM	Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update (GlobeNewswire)
Jul-28-22 08:00AM	Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022 (GlobeNewswire)
Jul-01-22 04:05PM	Achieve Life Sciences Announces Granting of New Hire Inducement Awards (GlobeNewswire)
Jun-29-22 08:00AM	Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation (GlobeNewswire)
Jun-21-22 08:00AM	Achieve Life Sciences Announces Participation at H.C. Wainwright 1st Annual Mental Health Conference (GlobeNewswire)
Jun-01-22 08:00AM	Achieve Life Sciences Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine e-cigarette Users (GlobeNewswire)
May-26-22 08:00AM	Achieve Life Sciences Announces Participation at LD Micro Invitational Conference (GlobeNewswire)
May-16-22 01:20PM	36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022 (ACCESSWIRE)
May-13-22 08:00AM	Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference (GlobeNewswire)
06:30AM	ACHV: First Quarter 2022 Results (Zacks Small Cap Research)
May-12-22 04:00PM	Achieve Reports Financial Results for First Quarter 2022 and Provides Corporate Update (GlobeNewswire)
May-05-22 02:59PM	Health Check: How Prudently Does Achieve Life Sciences (NASDAQ:ACHV) Use Debt? (Simply Wall St.)
Apr-28-22 05:22AM	ACHV: Topline Data from ORCA-2 Smoking Cessation Trial (Zacks Small Cap Research) -6.46%
Apr-27-22 09:40AM	Achieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking Cessation (Benzinga) +7.68%
08:00AM	Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers (GlobeNewswire)
Apr-21-22 08:00AM	Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 12, 2022 (GlobeNewswire)
Mar-15-22 08:00AM	Achieve Life Sciences Announces Cytisinicline Presentation at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting (GlobeNewswire)
Mar-14-22 08:00AM	Achieve Life Sciences Announces Appointment of Dr. Vaughn Himes to Board of Directors (GlobeNewswire)
Mar-11-22 08:06AM	ACHV: 2021 Results: ORCA-3 Underway, ORCA-V1 Soon to Start (Zacks Small Cap Research)
08:00AM	Achieve Life Sciences Announces Expansion of Manufacturing & Quality Operations Team and Granting of Inducement Award (GlobeNewswire)
Mar-10-22 08:00AM	Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2021 and Provides Corporate Update (GlobeNewswire)
Mar-08-22 08:00AM	Achieve Life Sciences Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-24-22 08:00AM	Achieve Life Sciences to Announce Fourth Quarter and Year-End 2021 Financial Results and Host Conference Call and Webcast on March 10, 2022 (GlobeNewswire)
Feb-04-22 04:37AM	ACHV: The Final Phase III Begins (Zacks Small Cap Research)
Feb-03-22 08:00AM	Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Award (GlobeNewswire)
Feb-02-22 08:00AM	Achieve Life Sciences Announces Participation in February Investor Conferences (GlobeNewswire)
Jan-28-22 10:07AM	36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022 (ACCESSWIRE)
Jan-25-22 11:08AM	Achieve Life Sciences Initiates Pivotal Trial Of Cytisinicline For Smoking Cessation (Benzinga)
08:00AM	Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation (GlobeNewswire)
Jan-06-22 08:30AM	Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference (GlobeNewswire)
Jan-04-22 08:30AM	Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation (GlobeNewswire)
Dec-22-21 12:16PM	Achieve Life Sciences Secures $25M Loan Facility To Fund Smoking Cessation Program (Benzinga)
08:30AM	Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical Development (GlobeNewswire)
Nov-23-21 08:30AM	Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessation (GlobeNewswire)
Nov-22-21 08:30AM	Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC) (GlobeNewswire)
Nov-11-21 04:20AM	We Think Achieve Life Sciences (NASDAQ:ACHV) Needs To Drive Business Growth Carefully (Simply Wall St.)
03:00AM	ACHV: Early 2022 Start to ORCA-3 and ORCA-V1 (Zacks Small Cap Research)
Nov-09-21 04:05PM	Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development (GlobeNewswire)
Nov-04-21 08:30AM	Achieve Life Sciences Announces Participation in November Investor Conferences (GlobeNewswire)
Nov-02-21 01:03PM	Achieve Life Sciences To Start Cytisinicline's Trial For Nicotine E-cigarette Cessation (Benzinga)
08:30AM	Achieve Life Sciences Announces FDA Acceptance of IND Application for Cytisiniclines Second Planned Indication for Nicotine E-cigarette Cessation (GlobeNewswire)
Oct-26-21 08:30AM	Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021 (GlobeNewswire)
Sep-15-21 05:30AM	Achieve Life Sciences to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Sep-14-21 05:30AM	Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference (ACCESSWIRE)
Sep-09-21 05:30AM	Achieve Life Sciences to Participate in Two Upcoming Investor Conferences (ACCESSWIRE)
Aug-16-21 05:10AM	ACHV: ORCA-2 Fully Enrolled (Zacks Small Cap Research) -6.46%
Aug-13-21 05:30AM	Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards (ACCESSWIRE)
Aug-11-21 04:05PM	Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update (ACCESSWIRE) +8.06%
05:30AM	Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen (ACCESSWIRE)
Aug-03-21 05:30AM	Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021 (ACCESSWIRE)
Jul-22-21 09:35AM	Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use (ACCESSWIRE)
Jul-12-21 05:57AM	ACHV: Longer Patents, Higher Valuation (Zacks Small Cap Research)
Jul-01-21 06:25AM	ACHV: Target Up On Longer Patent Life (Zacks Small Cap Research)
Jun-29-21 05:30AM	Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline (ACCESSWIRE)
Jun-13-21 02:11PM	Achieve Life Sciences, Inc. (ACHV) Fell Out Of Favor With Hedge Funds? (Insider Monkey)
Jun-03-21 05:30AM	Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of Addiction (ACCESSWIRE)
Jun-02-21 05:30AM	Achieve Life Sciences to Present at LD Micro Invitational XI Virtual Conference (ACCESSWIRE)
May-27-21 04:05PM	Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (ACCESSWIRE)
May-25-21 08:30AM	Achieve Life Sciences Announces Pricing of $20 Million Underwritten Public Offering (ACCESSWIRE) -15.39%
05:55AM	ACHV: ORCA-2 Enrollment On Track (Zacks Small Cap Research)
May-24-21 04:05PM	Achieve Life Sciences Announces Proposed Underwritten Public Offering (ACCESSWIRE) -5.68%

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bencich John	CEO	May 30	Buy	5.50	5,000	27,500	66,730	Jun 01 05:42 PM
JACOBS CINDY	President & CMO	Apr 28	Option Exercise	0.00	2,500	0	18,870	May 01 05:54 PM
Wan Jerry	Principal Accounting Officer	Apr 28	Option Exercise	0.00	1,250	0	7,101	May 01 05:55 PM
Bencich John	CEO	Apr 28	Option Exercise	0.00	7,500	0	63,557	May 01 05:53 PM
Stewart Richard Alistair	Executive Chairman	Apr 28	Option Exercise	0.00	5,000	0	30,751	May 01 05:51 PM
Wan Jerry	Principal Accounting Officer	Apr 21	Option Exercise	0.00	5,625	0	8,861	Apr 24 04:17 PM
Stewart Richard Alistair	Executive Chairman	Apr 21	Option Exercise	0.00	22,500	0	35,876	Apr 24 04:15 PM
JACOBS CINDY	President & CMO	Apr 21	Option Exercise	0.00	16,250	0	20,181	Apr 24 04:14 PM
Bencich John	CEO	Apr 21	Option Exercise	0.00	25,000	0	61,920	Apr 24 04:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACHV | Achieve Life Sciences, Inc.

Upgrade your FINVIZ experience